The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
29
Netarsudil eye drops instilled once daily
Placebo eye drops instilled once daily
Price Vision Group
Indianapolis, Indiana, United States
Change in Central Corneal Thickness
Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline
Time frame: 1 month
Change in Corrected Distance Visual Acuity (CDVA)
Change in CDVA (lines read on the eye chart at 3 months minus lines read at baseline)
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.